Chyluria: what does the clinician need to know?

Victoria Stainer, Patrick Jones, Siri Øvereng Juliebø, Rupert Beck and Amr Hawary

Abstract: Chyluria is secondary to the presence of chyle in the urine. The classical appearance on inspection is of milky white urine, which is caused by a fistulous communication between the lymphatic system and the urinary tract. Worldwide, it is most commonly associated with the parasite *Wuchereria bancrofti*, which is prevalent in Asia, most extensively in India but also China and Taiwan. However, in the United Kingdom, Europe and North America, where the condition is rare, non-parasitic aetiologies predominate. Chyluria is occasionally associated with other urinary tract symptoms including infection, loin pain and haematuria. It may also cause hypoproteinaemia, weight loss and cachexia. Management is based on identifying the aetiology and depends on the severity of the chyluria and presence of associated symptoms. Given its predominate symptom being urinary, cases in the West can fall under the care of the urologist. The aim of this article is to provide an overview and summary of the aetiology, assessment and management of chyluria based on the most up-to-date evidence available. This was achieved through a non-systematic review of world literature.

Keywords: chyluria, infection, kidney, lymphangiography, sclerotherapy

Introduction

In contemporary practice, an increasing numbers of cases of chyluria are being seen. This clinical condition is typically managed by a number of different specialities including nephrology, general medicine, infectious diseases and urology. Whilst still uncommon in the United Kingdom (UK) and the Western world, it is useful to understand the pathophysiological abnormalities that result in chyluria, in order to be able to formulate a practical approach to its diagnosis and management. The objective of our review is to provide such as understanding.

Methods

The authors performed a non-systematic review of world literature in order to identify relevant studies on chyluria. All article types were considered and no time restrictions were placed. Bibliographic databases searched included Pubmed/medline, Scopus, CINAHL and Google scholar.

Epidemiology

Chyluria remains endemic in parts of Asia, especially India and also Sub-Saharan Africa. Lymphatic filariasis, which is estimated to affect 120 million people worldwide, is often associated with this parasite, and chyluria can be a late manifestation of this disease in around 10% of cases. Non-parasitic causes of chyluria are reported to affect men and women in equal distribution; however, parasitic causes affect the former in up to 86% of cases. Chyluria is more prevalent in the rural population and is associated with lower socioeconomic status. However, cases caused by *Wuchereria bancrofti* are transmitted by Culex mosquitoes, which in areas of Sri Lanka are found in more urbanised areas.

Aetiology

Chyluria can be broadly classified into parasitic and non-parasitic causes; 95% of parasitic causes are attributed to *W. bancrofti*, with the remaining...
5% secondary to Taenia echinococcus, Taenia nana, Ankylostomiasis, Trichiniasis and the malarial parasite. Non-parasitic causes are rarer and these are almost always non tropical.3,4 Aetiological factors include blunt or penetrating trauma, a complication of surgery such as partial nephrectomy or aorto-iliac bypass, infection, malignancy, lymphatic malformation, radiation, abscess, congenital abnormalities, pregnancy and stenosis of the thoracic duct.5–9 Acute myeloid leukaemia and testicular cancer are the most commonly described malignancies, which are associated with chyluria10 (Table 1).

In addition to this, there exists an abundance of case reports in the world literature, which reveal a multitude of rare presentations and attributed causes. For example, chyluria has also been reported as a complication of retroperitoneal lesions in lymphangiomatosis and in children secondary to a congenital fistula between lymphatics and the bladder.11 Chyluria in children is very rare and under-reported, with the majority being described in case reports.12 In such cases there are no guidelines for management so it is likely the treatment will be tailored on a case-by-case basis.12 Chylous ascites and chyluria have been reported in nephrotic syndrome with focal segment glomerulosclerosis and nephrotic syndrome due to retroperitoneal lymphangioma.13 The authors identified one case report of chyluria presenting post-renal transplant with spontaneous resolution after 15 days.14

| Parasitic                  | Non-parasitic                                      |
|----------------------------|----------------------------------------------------|
| • Wuchereria bancrofti (95%)| • Trauma                                           |
| • Taenia echinococcus      | • Surgery                                          |
| • Taenia nana              | - Partial nephrectomy                              |
| • Ankylostomiasis          | - Aorto-iliac bypass                               |
| • Trichiniasis             | • Infections                                       |
| • Malaria                  | • Malignancy                                       |
|                            | • Lymphatic malformation                           |
|                            | • Radiation                                        |
|                            | • Abscess                                          |
|                            | • Congenital abnormalities,                        |
|                            | • pregnancy                                        |
|                            | • Lymphangioma of kidney or bladder                |
|                            | • Stenosis of thoracic duct                        |

**Table 1. Common causes of chyluria.**

Chyle is composed of albumin, emulsified fat and fibrin.15 Chyle enters the urinary tract subsequent to the rupture of lymphatic channels into the urinary tract leading to a lympho-urinary fistula. This occurs most commonly at the renal pelvis. However, the exact mechanism by which chyluria develops is unclear.16 It may be caused either by regurgitation of chyle from the lymphatic system into the renal tract or as a result of obstruction of the lymphatic system in the vicinity of the urinary tract resulting in the development of a fistula.9,17 The regurgitation theory is based upon either the build-up of toxic metabolites or an inflammatory immune reaction secondary to parasitic infestation resulting in the development of lymphatic ectasia and varicosities that rupture, releasing chyle from dilated intestinal lymphatics into the renal system. In the obstructive theory, there is oblitative lymphangitis secondary to the parasitic infections. This leads to collaterals and varicosities and eventually the backflow of chyle.18

**Presentation**
In 70% of cases of chyluria, patients present with the worrying appearance of milky white urine.4 Other signs and symptoms reported at the time of presentation include dysuria, urgency and urinary retention secondary to chylous-clot haematuria. Clot colic can also occur. Systemic symptoms include weight loss, chills and peripheral oedema.9 When associated with a parasitic cause, cases can present with concomitant genital manifestations, 25% with lymphatic obstruction in limbs, and 5% with cellulitis, abscesses and haematuria.10

Parasitic chyluria usually occurs between the ages of 20 and 40. However, it has been reported in children as young as 5 years.7 Prior to diagnosis, symptoms may have been present up to 11 years
in some reported cases.\textsuperscript{19} It can follow a relapsing and remitting course.

Those cases without a parasitic aetiology can appear at any age but tend to present later in life.\textsuperscript{12} The classical presentation is often milky white urine, with or without the associated features mentioned previously, which depends on the severity of the infection. When presenting as a complication of surgical intervention to the kidney, chyluria has been reported to present as late as 2 years following the procedure.\textsuperscript{4} Miller \textit{et al.} carried out a retrospective review of all computerised tomography (CT) imaging, which patients (\(n = 125\)) had undergone following partial nephrectomy\textsuperscript{20}; 3.2\% of patients had incidental findings of chyluria as a result of lymphatic injury. Of note, none of these patients required intervention for this. The only symptom reported in this patient population was intermittent, cloudy urine.

### Grading

There exists no universally accepted grading system for chyluria and a number of grading scales that are in current use have been described in world literature.\textsuperscript{21} Chyluria may be graded mild, moderate or severe (Table 2). The grading takes into account the degree of chyluria, associated symptomatology, episode frequency and the extent of calyceal involvement.\textsuperscript{17} Mild chyluria (34–50\% of cases) comprises intermittent milky urine with no other symptoms. Retrograde pyelograms studies show involvement of only a single calyx. Moderate chyluria (33–40\% of cases) is defined as intermittent continuous milky urine with occasional additional symptoms including clot colic or chylous coagulum, but not retention or weight loss. Retrograde studies reveal involvement of two or more calyces. Severe chyluria is characterised by continuous milky urine with the presence of one or more of the following: urinary retention, haematochyluria and systemic symptoms such as unintentional weight loss. Retrograde studies show involvement of most of the calyces with possible ureteric involvement. Of note, there is no defined amount of weight loss to qualify for this. Rather, it rests with the clinicians’ discretion.

A more recently developed alternative scale classifies chyluria Grade 1–3.\textsuperscript{22} Grade 1 consists of no more than one episode a year and no associated chylous clot(s). Grade 2 is where is also no more than one episode of chyluria a year but there is associated chylous clot and/or clot retention. For Grade 3 is when there has been two or more episodes a year and there is associated chylous clot and/or anaemia.

### Management

#### Investigations

**Laboratory.** The macroscopic appearance of chyluria is typically milky and may contain a semisolid gel, sometimes blood and fibrin clots.\textsuperscript{15} A post-prandial specimen of urine is recommended where possible.\textsuperscript{23} When left to settle, it separates into distinct layers of fat, fibrin and cellular debris, whilst after centrifugation it remains turbid. With the addition of a fat solvent such as ether, the urine should become clear, whilst the addition of Sudan III stain results in a superficial layer of red-stained fatty particles lying on clear urine after resting. An alternative method to this is to mix Sudan III with butter and for the patient to consume it.\textsuperscript{16} A positive test results in production of orange-pink urine. Estimation of urinary chylomicrons is the most specific and sensitive test for chyluria.\textsuperscript{17} Small lymphocytes, either individually

| Table 2. Grading of chyluria. |
|-------------------------------|
| **Mild chyluria**             |
| Clinical feature[s]           |
| Intermittent episodes milky urine |
| Retrograde study feature[s]   |
| Involvement of only a single calyx |
| **Moderate chyluria**         |
| Clinical feature[s]           |
| Intermittent episodes milky urine +/- clot colic |
| Retrograde study feature[s]   |
| Involvement of 2 or more calyces |
| **Severe chyluria**           |
| Clinical feature[s]           |
| Persistent milky urine AND One or more of the following: |
| • Urinary retention |
| • Haematochyluria |
| • Systemic symptoms for example, weight loss |
| Retrograde study feature[s]   |
| Involvement of most of the calyces with possible ureteric involvement |
or as a clump, can be seen with 1–2 drops of 1:1500 methylene blue. Of note, while phosphaturia has the same macroscopic appearance, it clears when a few drops of 5–10% acetic acid is added to a sample. Dalela et al. found that triglycerides are present in 100% of chyluria samples. Levels >15 mg/dl are indicative for chyluria. Higher levels of triglyceride resulted in greater haziness in the appearance of the patient’s urine. Some studies have found high urinary triglyceride and cholesterol levels a predictive factor for a worse response to sclerotherapy treatment.

For suspected parasitic causes, filarial antigen detection in the urine and serum can be done with immunochromatography or standard ELISA testing. The ELISA tests have a specificity of 85% and a sensitivity of 95%.

Radiological. Ultrasonography can be used to identify any renal abnormalities as well as blood clots with a chylous component. Intravenous pyelography is not usually used as intra renal/ureteric pressure is usually required in order to identify dilated para-calycetal lymphatics. CT can identify fat within the bladder and possible dilated lymphatics. Magnetic resonance imaging is most useful in cases where there is the possibility of a fistula in the lower ureter or bladder as it helps to delineate the anatomy more accurately. Renal biopsy can be used to diagnose glomerulonephritis if this is suspected to be part of the disease process.

Lymphangiography is the pre-operative imaging procedure of choice because it provides information on the site, size and the number of fistulous communications and has a sensitivity of 90%. It may also identify dysplasia of the lymphatic vessels, beading of the thoracic duct, dilated cisterna chyli, and abnormal lymphatics surrounding the ureters. It is not however routinely used because it is invasive, technically challenging and time consuming. Dong et al. recently published their experience and method of diagnostic lymphangiography followed by CT imaging within 60 min, which provided for assessment of redistribution of contrast medium. They determined this allowed for enhanced identification of lymphatic anomalies and the distribution of collateral lymphatic vessels.

Lymphangioscintigraphy allows for road mapping of the lymphatic transport and drainage system. It typically uses Tc99 human serum albumin sulphur colloid, is a safe and non-invasive way of diagnosing the site of a fistula. It also provides an assessment of the degree of reflux and is useful for detecting any possible recurrence. No side effects have been reported to date.

Endoscopy. Endoscopy can serve as an important part of the diagnostic process although is not necessary in every case and can be used in a more therapeutic role rather than just diagnostic. Endoscopic visualisation of the urinary tract via can help identify any obvious fistula. Furthermore, ureteric catheter(s) may be used to obtain split urinalysis to identify the affected side. Cystoscopy can also sometimes reveal an affected side where the milky urine is visualised as it effluxes from an ureteric orifice. Retrograde pyelography can be used to identify lymphatic backflow; however, the specificity associated with this is low as similar images can be seen with contrast when injected under pressure. The role of endoscopy including retrograde pyelography is decisive in patients who have not responded to conservative or medical therapy.

Diagnostic pathways. In the UK there is no clear consensus on the investigation protocol or algorithm for cases of chyluria. This is most likely due to its rarity, and the pathway adopted usually depends on the speciality overseeing the patient’s care, the resources available and the suspected cause. However, it is likely that after blood and urinary investigations the first line radiological investigations include a CT urogram and retrograde studies, largely owing to their availability. For non-parasitic chyluria, on-going management would be tailored based on the suspected cause and discussion with specialist centres can be sought.

Treatment

The management of chyluria ranges from conservative measures such as dietary changes to invasive management including surgery (Figure 1). It depends on the severity of symptoms and the underlying cause.

Conservative

The natural history of chyluria is unknown and up to 50% of cases may resolve spontaneously. Conservative management has a success rate of more than 70%. A high fluid intake is recommended and in mild cases, a modified diet such as high protein, multivitamins (A, D, E, K) and
Leafy green vegetables with fat restriction of <25 g/day can be sufficient. Fat-free diets are recommended where possible. An alternative is a low fat, medium-chain triglyceride (<12 carbon atoms) diets for example, using coconut oil for cooking, are recommended as these are absorbed directly through the portal system and bypass the intestinal lymphatics, which does not occur with long chain fatty acids. Sharma et al. proposed the concept of total parenteral nutrition in cases of intractable chyluria. There is limited information on the recommended length of conservative treatment. Limiting factors would be severity of symptoms and any concern regarding vitamin deficiencies.

In patients with lymphadenitis, bed rest, anti-inflammatories and analgesics are used for symptom control. Chylous clot can be managed with manual bladder washouts in the first instance. However, the presence of such clot often indicates that more than conservative treatment alone will be needed.

For those patients with suspected filarial infection, medication is used in combination with dietary

---

**Figure 1.** Diagnostic tests for suspected chyluria.
CT, computerised tomography; MRI, magnetic resonance imaging; USS, ultrasound scan.
modifications. Diethylcarbamazine (DEC), ivermectin, albendazole and benzathine penicillin are the most commonly pharmacotherapeutic options. The treatment protocol for DEC is 6 mg/kg/day for 21 days. This drug acts against the microfilaria, the larval phase of the parasite. Longer courses of DEC can be required and/or the treatment course can be repeated after 8 weeks if the response is unsatisfactory. Side effects can include itching, painful glands and skin rash. Febrile reaction can occur if the microfilaria burden is very high and so an antihistamine can be prescribed alongside the treatment course. Ivermectin is given as a single dose of 6–12 mg, which is then repeated after 3 weeks. Albendazole is a 10- to 14-day course of 400–800 mg/day and benzathine penicillin is taken for 12 weeks, 1.2 million units weekly. Combination drug treatments have also been applied and success is reported. In endemic areas treatment can be given without demonstrating filarial antigen if it is suspected. Bed rest and abdominal binders are also recommended. The latter serve raise the intra-abdominal pressure and thereby lower lympho-urinary reflux. However, the evidence supporting use of abdominal binders is weak (level of evidence 5).

Minimally invasive
The majority of minimally invasive techniques involve sclerotherapy and this is indicated in patients that have failed conservative or medical treatments. Many different agents having been used, such as silver nitrate 0.1–3%, 0.2% povidone iodine, 1–25% sodium iodide, 10–25% potassium bromide, 50% dextrose and hypertonic saline. Currently, 1% silver nitrate is the sclerosant of choice. Sclerotherapy, when instilled into the renal pelvis, reaches the lymphatics via the fistulous communication. From here, it induces a chemical lymphangitis with the oedema causing blockage of lymphatics and resulting in immediate relief. As fibrosis of lymphatics subsequently takes place, the relief is lasting. The procedure can be undertaken under local anaesthetic or sedation. A ureteric catheter is passed into the renal pelvis and 7–10 ml of sclerosant is injected until the patient reports pain. With regards to procedural timings, 3 days of instillations occurring every 8 h has been found to be superior to a once weekly instillation for 6 weeks. It is advised to only do one side at a time due to the risk of acute tubular necrosis. If both renal units are affected, a waiting period of at least 2 months is recommended before the contralateral side is treated.

Povidone iodine is a non-ionic and water soluble surfactant polymer, which can achieve an septic sclerosing and obliterative inflammatory reaction. It can also be used in combination with 50% dextrose. Singh et al. recently reported details of their sclerotherapy regimen. They prepared 0.2% povidone–iodine (5% povidone iodine 10 ml + distilled water 40 ml) and injected 5 ml of this solution into the renal pelvis. After 1 min, this was allowed to drain out. This was repeated until all the agent had been administered. The retrograde ureteric catheter, which had been used to deliver this sclerosing substance, was left in situ and this process was carried out again twice more, at 48 h and 96 h after the initial procedure respectively. A total of three sessions are performed in their method and antibiotic cover was administered over the treatment period. Sclerotherapy can be associated with minor and self-limiting adverse effects such as nausea, flank pain and haematuria. These should resolve within 48 h. Several isolated reports do exist of more serious sequelae including renal failure, anuria with pelvi-calyceal cast formation and acute necrotizing ureteritis.

Goel et al. carried out a prospective, randomised study which compared 1% silver nitrate, 0.2% povidone iodine and 50% dextrose. While the 50% dextrose arm was discontinued early on due to a very poor success, no significant difference in efficacy was found between povidone iodine and silver nitrate. The authors highlighted that silver nitrate is arguably associated with more disadvantages such as its susceptibility to light, water insolubility and need for autoclaving. The latter can cause water evaporation and therefore presents challenges in quality assurance and maintaining an accurate concentration. In contrast povidone iodine is more readily available, cheaper, easier to reconstitute and stable at room temperature. Purkait et al. added to the body evidence supporting endoscopic sclerotherapy and performed a prospective study using dimercapto-succinic acid renal imaging to evaluate if there is any adverse effect on renal function associated with this treatment method. The authors concluded that relative renal function does not deteriorate by more than 5%.

Other minimally invasive techniques reported on in literature include heat-clearing and endoscopic coagulation. Pavlinec et al. recently described their method of using flexible ureteroscopy to pinpoint a fistulous opening in the renal pelvis.
after retrograde studies had revealed an irregularity at this site. This pyelolymphatic fistula had presented 4 weeks after robotic pyeloplasty. The authors then used endoscopic fulgaration to successfully treat the patient.

**Invasive**

Truly invasive management of chyluria is reserved for those with significant symptoms and in whom medical or minimally invasive treatment options have failed. The latter include patients who have not responded to two or more courses of sclerotherapy. Overall surgical techniques have a reported 95% success rate. The operative techniques described for chyluria include chylolymphatic disconnection and creation of lymphovenous anastomoses, which may be retroperitoneal lymphovenous anastomosis, transinguinal spermatic lymphovenous anastomosis or inguinal lymph node-saphenous venous anastomosis. Other surgical procedures include auto-transplantation or nephrectomy. Open surgical methods are now possible laparoscopically or robotically, which offer the advantages of reduced morbidity, duration of stay and pain. The process of lympho-venous disconnection was first described in the 1950s. This is still the most frequently performed operation and a modified technique involves only performing medial lymphatic disconnection, reducing operating time, morbidity and excess dissection with good results. Pre-operatively, the patient eats a high fat diet then undergoes lymphangiography (+/– methylene blue injection) to identify the abnormal lymphatic channels. It typically involves the following steps: nephron-lympholysis, hilar stripping, uretero-lympholysis, fasciectomy and nephropexy. Overall success rates for chylolymphatic disconnection have been reported as high as 98%.

Recurrence

Recurrence of chyluria after initial clearance has been reported in up to 80% of patients managed conservatively. For sclerotherapy this is improved significantly to 13–41%. However, primary treatment failure with sclerotherapy is between 10 and 20%. Recurrence of chyluria post intervention is usually due to incomplete stripping, reflux from contralateral side, and reflux from bladder. Methods to prevent recurrence involve the use of an omental wrap, or use of augmented visualisation techniques such as magnifying loops or an operating microscope. Not all cases of recurrence warrant invasive treatment such as surgery.

Pregnancy

Whilst chyluria is less common in females (9:1 male to female ratio) and rare in pregnancy, it is not uncommon in endemic areas. It most commonly presents in the second trimester (74.4%). The causes of nonparasitic chyluria are the same as previously listed and the clinical presentation is the same. Observation of the disease’s natural history have commented that the condition severity can worsen as pregnancy progresses.

The overall management is more challenging as the pharmacotherapeutic options are more limited. Anti-filarial drugs have a potentially teratogenic risk and are advised against by the World Health Organisation (WHO) and Federal Drug Agency (FDA). However, Gyapong et al. reported outcomes from a community filariasis program where they found pregnant patients had been inadvertently treated with ivermectin and...
Therapeutic Advances in Urology 12

albendazole. There was no significant association with greater risk of birth defect or congenital malformations in these child bearing women.49 The mainstay of treatment for these patients is conservative and supportive. Sclerotherapy has been used but there is no universal treatment protocol which is largely due to the lack of studies in this area. Mahmood et al. reported their tertiary unit’s experience of managing chyluria in pregnant patients; 13/43 and 19/43 experienced resolution after one and two sclerotherapy treatments respectively.4 Patients undergoing this treatment are acknowledged to be at greater risk of infectious complications.22 Where possible, treatment can be deferred until after the birth. Patients who are near term can be considered for planned caesarean section.

Conclusion
While extremely rare in the UK, clinicians need an understanding of the natural history of chyluria and how to investigate and manage it accordingly. The mainstay of investigation lies in confirming the diagnosis of chyluria via analysis of urine for chylomicrons and determining the site of the fistula using lymphangioscintigraphy, retrograde studies or endoscopic visualisation of the urinary tract. Medical management alone is successful in up to 70% of cases, severe cases may require intervention with sclerotherapy and refractory cases with surgical intervention with a 99% success rate.36

Author contributions
VS contributed to conception, design, literature search and draft. PJ contributed to draft and revision and literature search. SOJ and RB to critical review, revision and expertise. AH supervised projected, conceived idea and helped revise each version.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Guarantor
AH

ORCID iD
Patrick Jones https://orcid.org/0000-0003-4253-1283

References
1. Tan Y. Chyluria in non-filarial endemic areas: an internist’s perspective. BMJ Case Rep 2017; 2017: bcr201720772.
2. Jones RT. Non-endemic cases of lymphatic filariasis. Trop Med Int Health 2014; 19: 1377–1383.
3. Sinha RK, Ranjan N, Singh N, et al. Chyluria: a scourge of our region. BMJ Case Rep 2015; 2015: bcr2014209188.
4. Abeygunasekera AM, Sutharshan K and Balagobi B. New developments in chyluria after global programs to eliminate lymphatic filariasis. Int J Urol 2017; 24: 582–588.
5. Komeya M, Sahoda T, Sugiiura S, et al. Chyluria after partial nephrectomy: a rare but considerable complication. Int J Urol 2013; 20: 242–245.
6. Yamauchi S. Chyluria: clinical, laboratory and statistical study of 45 personal cases observed in Hawaii. J Urol 1945; 54: 318–347.
7. Onyecije CI, Sherer DM and Trampert J. Nonfilarial chyluria during pregnancy. Obstet Gynecol 1997; 90: 699–700.
8. Yu HH, Nga H and Leong CH. Chyluria—a 10-year Follow-up. Br J Urol 1978; 50: 126–133.
9. Dalela D. Issues in etiology and diagnosis making of chyluria. Indian J Urol 2005; 21: 18–23.
10. Panchal VJ, Chen R and Ghahremani GG. Nontropical chyluria: CT diagnosis. Abdom Imaging 2012; 37: 494–500.
11. Guillonneau B, Bouchot O, Buzelin F, et al. Lymphangiomyomatosis: an exceptional cause of chyluria. Report of a case. Prog Urol 1993; 3: 484–489.
12. Stalens JP, Falk M, Howmann-Giles R, et al. Milky urine – a child with chyluria. Eur J Pediatr 1992; 151: 61–62.
13. Lewsuwan S, Kanjanabuch T, Avihingsanon Y, et al. A rare case of chylous ascites and chyluria in an adult nephrotic syndrome with focal segmental glomerulosclerosis. J Med Assoc Thai 2006; 89(Suppl. 20): S253–S256.
14. Yilmaz VT, Dinc B, Ay N, et al. Chyluria and delayed graft function in early port–transplant period in renal transplant patient. Am J Med Sci 2010; 340: 169–172.
15. Singh I, Darhan P and Sharma N. Chyluria – a clinical and diagnostic stepladder algorithm with review of literature. Indian J Urol 2004; 20: 79–85.

16. Wiggelinkhuizen J, Landman C and Greenberg E. Chyluria. Am J Dis Child 1972; 124: 99–101.

17. Aye UT and Aung ST. Chyluria. Br J Radiol 1975; 26: 237–242.

18. Goel TC and Goel A (eds). Chyluria. In Lymphatic Filariasis. Singapore: Springer, 2016, pp.273–300.

19. Tandon V, Singh H, Dwivedi US, et al. Filarial chyluria: long-term experience of a university hospital in India. Int J Urol 2004; 11: 193–198.

20. Miller F, Keppke A, Yaghmai, et al. CT diagnosis of chyluria after partial nephrectomy. AJR 2007; 188: W25–W28.

21. Gutilla A, Beltrami P, Bettin L, et al. Chyluria: the state of the art. Urologia 2017; 84: 65–70.

22. Purkait B, Garg G, Singh M, et al. Chyluria in pregnancy: etiology, diagnosis, and management perspective. Saudi J Kidney Dis Transpl 2019; 30: 309–314.

23. Gutilla A, Beltrami P, Bettin L, et al. Non-parasitic chyluria: our experience with sclerotherapy with solution of povidone-iodine and dextrose and a review of the literature. Urol Case Rep 2016; 8: 28–30.

24. Rahman MM. Easy method of detection of chyle in urine. Indian J Nephrol 2012, 22: 147–148.

25. Mehta VK, Lohar H, Banerjee BK, et al. Surgical filariasis; immunoscreening for filarial IgG antibodies using Wuchereria bancrofti microfilarial excretory-secretory antigen. J Commun Dis 1999; 31: 35–40.

26. Sharma S and Hemal AK. Chyluria – an overview. Int J Nephrol Urol 2009; 1: 14–26.

27. Arrivé L, Monnier-Cholley L and El Mouhadi S. Use of unenhanced MR lymphography to characterize idiopathic chyluria. AJR Am J Roentgenol 2018; 211: W200.

28. Ngan H and Leong CH. A lymphographic study of chyluria. Br J Radiol 1977; 50: 863–870.

29. Pui MH and Yueh TC. Lymphoscintigraphy in chyluria, chyloperitoneum and chylothorax. J Nucl Med 1998; 39: 1292–1296.

30. Dong Jian, Xin J, Shen W, et al. Unipedal diagnostic lymphangiography followed by sequential CT examinations in patients with idiopathic chyluria: a retrospective study. AJR Am J Roentgenol 2018; 210: 792–798.

31. de Araújo PSR, Júnior VRS, Souza A, et al. Chyluria in a lymphatic filariasis endemic area. BMC Res Notes, 2018; 11: 269.

32. Uzu T, Takamori K, Fujino Y, et al. Idiopathic chyluria with nephrotic-range proteinuria and hypothyroidism. Intern Med 2019; 58: 1307–1309.

33. Singh H, Singla A and Jain A. Chyluria—a review of literature and a modified sclerotherapy regimen. Turk J Urol 2019; 45(Suppl. 1): S174–S177.

34. Garg M, Dalela D and Goel A. Devastating complication of silver nitrate instillation for the treatment of chyluria. BMJ Case Rep 2013; 2013: 1–3.

35. Mitsunari K, Imasato Y and Tsurusaki T. Preliminary study of a single instillation of low-concentration high-volume silver nitrate solution for chyluria: is >10 ml instillation an absolute contraindication in the real world? Trop Med Infect Dis 2019; 4: pii: E128.

36. Goel S, Mandhani A, Srivastava A, et al. Is povidone iodine an alternative to silver nitrate for renal pelvic instillation sclerotherapy in chyluria? BJU Int 2004; 94: 1082–1085.

37. Purkait B, Goel A, Deswal S, et al. Does endoscopic sclerotherapy in filarial chyluria affect renal function and morphology? A prospective study using dimercapto succinic acid renal scan. Asian J Urol 2019; 6: 359–363.

38. Pavlinec J, Rabley A, Kwenda E, et al. Endoscopic management of chyluria due to pyelolymphatic fistula after robot-assisted laparoscopic pyeloplasty. J Urol 2020; 203(Suppl. 4): e473–e473.

39. Lin TP, Hsu YS, Chen KK, et al. Chyluria – experience of Taipei veterans general hospital. J Chin Med Assoc 2003; 66: 109–112.

40. McGuinness LA and Prasad Rai B. Robotics in urology. Ann R Coll Surg Engl 2018; 100(Suppl. 6): 45–54.

41. You W, Luan B, Cheng T, et al. The efficacy and safety of retroperitoneoscopic renal pedicle ligation of lymphatic disconnection versus open surgery in the treatment of chyluria: a systematic review and meta-analysis. Clin Nephrol 2019; 91: 211–221.

42. Tung JYM, Chen K and Sim ASP. Indocyanine green-guided laparoscopic renal pedicle lymphatic disconnection: a novel, targeted treatment for chyluria. Int Braz J Urol 2019; 45: 1075.

43. Dalela D, Gupta VP, Goel A, et al. Omental wrap around the renal pedicle: an adjunctive
step to minimize morbidity and recurrence after lymphorenal disconnection for chyluria. *BJU Int* 2004; 94: 673–674.

44. Hou LQ, Liu QY, Kong QY, *et al.* Lymphonodovenous anastomosis in the treatment of chyluria. *Chin Med J (Engl)* 1991; 104: 392–394.

45. Núñez CM, Cárcamo PV, Kabani MH, *et al.* Recurrent nonparasitic chyluria. *Arch Exp Urol* 1998; 51: 932–934.

46. Mount P and Thong M. Perirenal lymphatic filariasis presenting as chyluria during pregnancy. *Kidney Int* 2006; 69: 2115.

47. Mahmood K, Ahmad A, Kumar K, *et al.* Chyluria in pregnancy – a decade of experience in a single tertiary care hospital. *Nephrourol Mon* 2015; 7: e26309.

48. Crompton DW. *Preventive chemo-therapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers.* Switzerland: World Health Organization, 2006.

49. Gyapong JO, Chinbuah MA and Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. *Trop Med Int Health* 2003; 8: 1093–1101.